Compare GSK plc (GSK) vs Lucid Group Inc (LCID) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Lucid Group Inc — how do they compare? GSK plc trades at $46.59 (market cap $91.88B), while Lucid Group Inc trades at $3.78 (market cap $1.51B). The key difference: GSK plc is far larger — about 60.8× Lucid Group Inc's market cap, and GSK plc pays a 3.9% dividend while Lucid Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Lucid Group Inc for 45 Days on average.
| GSK | LCID | |
|---|---|---|
Market Cap | $91.88B | $1.51B |
Volume | 7,730,529 | 12,333,745 |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $21.92 |
52-Week Low | $43.24 | $3.82 |
Typical Hold Time | 93 Days | 45 Days |
Enterprise Value | $111.88B | $4.40B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Lucid Group (LCID) trades at $3.785, down 2.7% with a bearish technical outlook. The company shows concerning fundamentals with negative profit margins (-249.21% net income margin) and consistent earnings misses. Recent news highlights operational challenges including delayed Cosmos SUV launch and aggressive cost-cutting targets of $1.4 billion for 2026. Cash flow remains negative at -$566 million, though strategic partnerships with Bolt for autonomous vehicles provide some growth potential.
LCID faces significant execution risks amid high cash burn and competitive EV market pressures. Analyst consensus is cautious with 67% hold ratings and $7.60 price target suggesting 101% upside potential. The stock presents high-risk speculation for investors betting on successful turnaround execution and partnership developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →
